CLOMID
LOE ApproachingNDAORALTABLETPriority Review
Approved
Feb 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
CLOMID by Sanofi is clinical pharmacology action clomiphene citrate is a drug of considerable pharmacologic potency. Approved for ovulatory dysfunction in women desiring pregnancy. First approved in 1967.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLOMID (clomiphene citrate) is an oral small-molecule fertility agent approved in 1967 that selectively modulates estrogen receptors in the hypothalamus, pituitary, and ovary to trigger ovulation. It works by blocking estrogen-receptor feedback, causing increased gonadotropin release and subsequent follicular development and ovulation. The drug is indicated for anovulatory women desiring pregnancy.
$0.564MPart D
LOE ApproachingAs CLOMID approaches loss of exclusivity, the brand team is likely transitioning to mature-market management with reduced headcount and focus on pricing defense and generic transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Action Clomiphene citrate is a drug of considerable pharmacologic potency. With careful selection and proper management of the patient, clomiphene citrate has been demonstrated to be a useful therapy for the anovulatory patient desiring pregnancy. Clomiphene citrate is capable…
Worked on CLOMID at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.